Medicine by the Numbers

A Collaboration of TheNNT.com and AFP

Leukotriene Receptor Antagonists in the Treatment of Acute Asthma

 

Am Fam Physician. 2016 Apr 1;93(7):552.

image

 Enlarge     Print

LEUKOTRIENE RECEPTOR ANTAGONISTS IN THE TREATMENT OF ACUTE ASTHMA

BenefitsHarms

No patient-important benefits

No hospital admissions were prevented

LEUKOTRIENE RECEPTOR ANTAGONISTS IN THE TREATMENT OF ACUTE ASTHMA

BenefitsHarms

No patient-important benefits

No hospital admissions were prevented

Details for This Review

Study Population: Patients two years and older with an acute asthma exacerbation, being treated with short-acting beta agonists and systemic corticosteroids

Efficacy End Points: Hospital admission, forced expiratory volume in one second (FEV1)

Harm End Points: Headache

Narrative: According to the Centers for Disease Control and Prevention, asthma accounts for 1.8 million emergency department visits and approximately 3,400 deaths annually.1 Despite these numbers, physicians have few options in the treatment of acute asthma if corticoste-roids, short-acting inhaled beta agonists, and magnesium have been ineffective. This review evaluates leukotriene receptor antagonists (LTRAs) as an additional treatment option in the emergency care setting.

This review included 1,940 emergency department patients with acute asthma, 470 of whom were children (two to 12 years of age).2 Intravenous and oral LTRAs were studied. No significant difference in hospitalization rate was observed in any group. A small statistically significant difference was noted in FEV1 improvement for oral zafirlukast (Accolate) and intravenous montelukast (Singulair; mean difference of 8% and 12% improvement from baseline FEV1, respectively) in adults only. This difference was not observed in children or in adults receiving oral montelukast. There was no difference in reported headaches for patients who received LTRAs vs. placebo.

Caveats: According to this review, LTRAs possibly improve FEV1 in adults, but they do not decrease hospital admission. This information may open the door for more studies, but it should not change clinical practice for several reasons. First, improvement in FEV1 is not a patient-oriented outcome. Also, all of the studies that showed improvement in FEV1 were analyzing it as a secondary end point (the primary end point was hospital admission). Finally, all studies of oral3,4 and intravenous5,6 LTRA therapy were published by a single principal investigator.

Although we need more options for patients with asthma if traditional therapies are ineffective, the data show that LTRAs do not appear to be a solution.

This series is coordinated by Dean A. Seehusen, MD, MPH, AFP Contributing Editor, and Daniel Runde, MD, from the NNT Group.

A collection of Medicine by the Numbers published in AFP is available at http://www.aafp.org/afp/mbtn.

Author disclosure: No relevant financial affiliations.

REFERENCES

show all references

1. Centers for Disease Control and Prevention. Asthma Facts—CDC's National Asthma Control Program Grantees. Atlanta, Ga.: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, July 2013. http://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf. Accessed March 2, 2016....

2. Watts K, Chavasse RJ. Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database Syst Rev. 2012;(5):CD006100.

3. Silverman RA, Nowak RM, Korenblat PE, et al. Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial. Chest. 2004;126(5):1480–1489.

4. Silverman RA, Korenblat PE, Nowak RM, et al. Zafirlukast improves emergency department outcomes and reduces relapses after an acute asthma episode. Eur Respir J. 2000;16(suppl 31):524s.

5. Camargo CA Jr, Smithline HA, Malice MP, Green SA, Reiss TF. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med. 2003;167(4):528–533.

6. Camargo CA Jr, Smithline HA, Gurner DM, et al. Evaluation of intravenous montelukast as an adjunctive treatment of acute asthma. Am J Respir Crit Care Med. 2008;177(suppl):A71.

 

 

Copyright © 2016 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Jun 15, 2017

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article